Volume 34, Number 1, January-February 2020

Contents

Reviews

Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids. C. HOLZMANN, W. KUEPKER, B. ROMMEL, B. HELMKE, J. BULLERDIEK (Rostock; Baden Baden-Buehl; Bremen; Stade, Germany) .................................................................................................................................... 1


Experimental Studies


Contents continued on the back cover
Editorial Board

I. ABRAHAM, The HOPE Center, University of Arizona, Tucson, AZ, USA
N.J. AGNANTIS, Department of Pathology, University of Ioannina, Ioannina, Greece
D. ANDERSON, Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, UK
V. BARAK, Department of Oncology, Hadassah University Hospital, Jerusalem, Israel
M.H. BARCELLOS-HOFF, Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA
K. BEIER, Department of Histology, University of Basel, Basel, Switzerland
M. BERGQVIST, Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden
R. BJERKVIG, Norlux Neuro-Oncology, Department of Biomedicine, University of Bergen, Bergen, Norway
W. BOWNE, Department of Surgery, Drexel University College of Medicine, Philadelphia, PA, USA
M. CARAGLIA, Department of Experimental Oncology, National Institute of Tumours Fondazione G. Pascale, Naples, Italy
P. CHANDRA, Department of Molecular Biology, Frankfurt University, Frankfurt am Main, Germany
J.-G. CHUNG, Department of Medicine, China Medical College, Taichung, Taiwan, ROC
L.A. COHEN, Northampton, MA, USA
A.I. CONSTANTINOU, Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus
T. DALIANIS, Department of Pathology-Oncology, Karolinska Institute, Stockholm, Sweden
D.T. DENHARDT, Division of Life Sciences, Rutgers University, Bridgewater, NJ, USA
W. DEN OTTER, VUMC - Department of Urology, Amsterdam, The Netherlands
K. DE MEIRLEIR, Department of Human Physiology and Medicine, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium
L. DE RIDDER, Department of Anatomy, Embryology and Histology, University of Ghent, Ghent, Belgium
E.P. DIAMANDIS, Department of Pathology and Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada
J.M. DRAKE, Division of Medical Oncology, RBHS-Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
T. EFFERTH, Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Germany
W. ENGSTRÖM, Department of Molecular Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden
M. ESKELINEN, Department of Surgery, University Hospital of Kuopio, Kuopio, Finland
J.A. FERNANDEZ-POL, Metalloproteomics, LLC, Chesterfield, MO, USA
G. FIORENTINI, UOC Oncologia, Azienda Ospedaliera Marche Nord, Pesaro, Italy
P.B. FISHER, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA
I. FREITAS, Dipartimento di Biologia Animale, University of Pavia, Pavia, Italy
M. FRIEDRICH, Department of Obstetrics and Gynecology, Klinikum Krefeld, Krefeld, Germany
R.E. FRIEDRICH, Department of Oral and Maxillofacial Surgery, Eppendorf University Hospital, Hamburg, Germany
R. GANAPATHI, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
G. GITSCH, Department of Gynecology and Obstetrics, University of Freiburg Medical Center, Freiburg, Germany
V. GORGOULIS, Department of Histology-Embryology, Medical School, University of Athens, Greece
J.S. GREENBERGER, Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA
J.W. GREINER, National Cancer Institute, NIH, Bethesda, MD, USA
D.S. GRIDLEY, Department of Radiation Medicine, Radiation Research Laboratories, Loma Linda University and Medical Center, Loma Linda, CA, USA
C.J. GRUBBS, Department of Nutrition Sciences, University of Alabama, Birmingham, AL, USA
F. GUADAGNI, IRCCS San Raffaele, Rome, Italy
D. RUBELLO, Department of Nuclear Medicine, PET Unit, S. Maria della Misericordia Hospital, IOV, Rovigo, Italy
C.A. RUBIO, Karolinska Institute, Pathology Research Laboratory, Stockholm, Sweden
G.R. RUTTEMAN, Department of Clinical Sciences of Companion Animals, University of Utrecht, Utrecht, The Netherlands
H. SAKAGAMI, Department of Dental Pharmacology, Meikai University School of Dentistry, Saitama, Japan
G. SAVA, Institutes of Biological Research, Fondazione Callerio-Onlus, Trieste, Italy
D. SCHIFFER, Neuro-bio-oncology Center, Policlinico di Monza Foundation, University of Turin, Vercelli, Italy
L.D. SHULTZ, The Jackson Laboratory, Bar Harbor, ME, USA
G. SICA, Istituto di Istologia ed Embriologia, Universita Cattolica del Sacro Cuore, Roma, Italy
J.M. SIEGFRIED, Department of Pharmacology, MNPI Center, University of Minnesota, Minneapolis, MN, USA
J. SLANSKY, Integrated Department of Immunology, School of Medicine, University of Colorado Denver and National Jewish Health, Denver, CO, USA
R.M. SNAPKA, Department of Radiology, The Ohio State University, Columbus, OH, USA
G.-I. SOMA, Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan
P.P. SORDILLO, Department of Medical Oncology and Hematology, Lenox Hill Hospital, New York, NY, USA
T.A. SPRINGER, Department of Pathology, Harvard Medical School, Boston, MA, USA
D.D. SPYROPOULOS, Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA
K. SYRJÄNEN, Biohit Healthcare Oyj, Helsinki, Finland
G.C. TORRE, Centro Ippocrate, Vico Cosmelli 4, Finale Ligure (SV), Italy
B. TRIBUKAIT, Department of Medical Radiobiology, Karolinska Hospital, Stockholm, Sweden
J. VADGAMA, Department of Internal Medicine, Charles E. Drew University of Medicine and Science, Los Angeles, CA, USA
J.K. VISHWANATHA, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX, USA
W. WANG, Research Institute of Healthcare Science, University of Wolverhampton, Wolverhampton, UK
N. WATANABE, Department of Clinical Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
W. WEBER, Clinical Cancer Etiology Unit, Basel, Switzerland
L.M. WEINER, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
J.A. WERNER, Department of Otolaryngology, Head and Neck Surgery, Marburg, Germany
S. YLÄ-HERTTUALA, Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, Finland
H. YOSHIDA, Department of Pathology, Kagoshima University, Kagoshima, Japan
## Acknowledgements

The following Organisations supported many of the works published in IN VIVO, Volume 33, 2019.

2017 Young Medical Science Researcher Grants, Ewha Womans University College of Medicine, Seoul, Republic of Korea
90th Anniversary of Chulalongkorn University Fund, Chulalongkorn University, Bangkok, Thailand
Academia Sinica, Taipei City, Taiwan, R.O.C.
Ajou University Medical Center, Suwon, Republic of Korea
AO Foundation, Davos, Switzerland
Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea
AstraZeneca plc, Cambridge, U.K.
Australia Awards PhD Scholarship, Department of Foreign Affairs and Trade, Barton, Australia
Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Science and ICT, Gwacheon, Republic of Korea
BEGO Implant Systems GmbH & Co. KG, Bremen, Germany
Bio & Medical Technology Development Program, National Research Foundation of Korea (NRF), Ministry of Science and ICT, Gwacheon, Republic of Korea
Biosignature Project and Biomarker Project, Academia Sinica, Taipei, Taiwan, R.O.C.

Chang Bing Show Chwan Memorial Hospital, Lukang, Taiwan, R.O.C.
Chang Gung Memorial Foundation, Taipei City, Taiwan, R.O.C.
Cheng-Hsin General Hospital, Taipei City, Taiwan, R.O.C.
China Medical University Beigang Hospital, Beigang, Taiwan, R.O.C.
China Medical University Hospital, Taichung, Taiwan, R.O.C.
China Medical University, Taichung, Taiwan, R.O.C.
China Scholarship Council (CSC) Grant, Ministry of Education of the People's Republic of China, Beijing, P.R. China
Chonnam National University Hospital Biomedical Research Institute, Gwangju, Republic of Korea
Chosun University Research Aid Scholarship Program, Gwangju, Republic of Korea
Chugai Co., Ltd., Tokyo, Japan
Chulalongkorn University, Bangkok, Thailand
Consejo Nacional De Ciencia y Tecnología (CONACyT), México, Mexico
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasilia, Brazil
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasilia, Brazil

Czech University of Life Sciences, Prague, Czech Republic
Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, R.O.C.
Dental Research Center, Nihon University School of Dentistry, Tokyo, Japan
Department of Life Science, Gachon University, Seongnam, Republic of Korea
Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan
Department of Molecular and Cellular Biology, Wroclaw Medical University, Wroclaw, Poland
Department of Molecular Cell Biology and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA, U.S.A.
Department of Pathology, Lake Erie College of Osteopathic Medicine, Erie, PA, U.S.A.
Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan
Division of Hematology, Barnes-Jewish Hospital, St. Louis, MO, U.S.A.
Endowment Fund, Chulalongkorn University, Bangkok, Thailand
Executive Unit for Financing Higher Education, Research Development and Innovation (UEFISCDI), Romania
Experimental Research Center of ‘ELPEN’, Pikermi, Greece
Faculty of Dentistry, University of Barcelona, Barcelona, Spain
Faculty of Dentistry, University of La Frontera, Temuco, Chile
Faxitron, Tucson, AZ, U.S.A.
Finnish Medical Association, Helsinki, Finland
Flinders Medical Centre Foundation Seeding Grant, Bedford Park, Australia
Franz-Penzoldt-Zentrum, Erlangen, Germany
Fundacao Araucaria, Curitiba, Brazil
G. Pascale Foundation, National Tumor Institute, Naples, Italy
Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan
Gencurix Inc., Seoul, Republic of Korea
Genentech, South San Francisco, CA, U.S.A.
Gerhard Domagk Grant, University Medicine Greifswald, Greifswald, Germany
German Federal Ministry of Education and Research, Bonn, Germany
Grant for International Research Integration: Research Pyramid, Ratchadaphiseksomphot
Grants-in-Aid for Scientific Research (KAKENHI), Japan Society for the Promotion of Science, Tokyo, Japan
Handok Inc., Seoul, Republic of Korea
Hannover Biomedical Research School, Hannover, Germany
Hannover Medical School, Hannover, Germany
Heilongjiang Bayi Agricultural University, Daqing, P.R. China
Hellenic Endocrine Society, Athens, Greece
Hellenic Foundation for Research and Innovation (HFRI), Athens, Greece
Hellenic Study Group of Psychoneuroimmunology in Cancer, Athens, Greece
HFRI PhD Fellowship Grant, General Secretariat for Research and Technology (GSRT), Athens, Greece
Industrial Technology Innovation Program, Ministry of Trade, Industry, & Energy (MOTIE), Sejong, Republic of Korea
Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
International Research Integration: Chula Research Scholar, Chulalongkorn University, Bangkok, Thailand
Intramural Research Fund, Ajou University Medical Center, Suwon, Republic of Korea
Istanbul University Scientific Projects Unit, Istanbul, Turkey
Italian Ministry of Health, Rome, Italy
Jilin Provincial Health Department Project of China, Jilin, P.R. China
Kafkas University, Kars, Turkey
Kanagawa Standard Anti-cancer Therapy Support System, Japan
Klin-StrucMed Program, Else-Kröner-Foundation (Else-Kröner-Stiftung), Bad Homburg vor der Höhe, Germany
Korea Health Technology R&D Project, Korea Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Seoul, Republic of Korea
Korea Research Institute of Bioscience and Biotechnology (KRIIBB), Daejeon, Republic of Korea
Korean Research Institute of Bioscience and Biotechnology Research Initiative Program, Daejeon, Republic of Korea
Krajska zdravotni, a.s, Ústí nad Labem, Czech Republic
Kyungpook National University Research Fund, Daegu, Republic of Korea
Leibniz-Institut für Plasmaforschung und Technologie e.V. (IPF), Greifswald, Greifswald, Germany
Lions Melvin Jones Eye Bank, Genoa, Italy
Mackay Medical College, New Taipei City, Taiwan, R.O.C.
Marie Skłodowska-Curie Grant, Horizon 2020 Research and Innovation Programme, European Union
Medical Center – University of Freiburg, Freiburg im Breisgau, Germany
Medical Research Core Facilities Center, Office of Research & Development at China Medical University, Taichung, Taiwan, R.O.C.
Meikai University School of Dentistry, Sakado, Japan
Ministry of Education and Scientific Research, Bucharest, Romania
Ministry of Education, Culture, Sports, Science and Technology of Japan, Tokyo, Japan
Ministry of Education, Youth and Sports, Prague, Czech Republic
Ministry of Science and Higher Education, Warsaw, Poland
Ministry of Science and Technology (MOST), Taipei, Taiwan, R.O.C.
Ministry of Trade, Industry and Energy (MOTIE), Sejong City, Republic of Korea
National Center for Genome Medicine (NCGM), Taipei, Taiwan, R.O.C.
National Centre for Research and Development in Poland, Warsaw, Poland
National Health Research Institute of Taiwan, Miaoli, Taiwan, R.O.C.
National Institute of Environmental Research, Incheon, Republic of Korea
National Institute of Health Sciences (NIHS), Tokyo, Japan
National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, U.S.A.
National R&D Program for Cancer Control, Ministry of Health and Welfare, Sejong, Republic of Korea
National Science Centre (NCN), Warsaw, Poland
Nestlé Nutrition Council Japan, Tokyo, Japan
Next-Generation BioGreen 21 Program, Ministry of Trade, Industry, & Energy (MOTIE), Sejong, Republic of Korea
Nihon University Multidisciplinary Research Grant, Nihon University, Tokyo, Japan
Non-profit Organization (NPO) for Supporting Clinical Research, Japan
Novartis Pharmaceuticals Corporation, Hanover, NJ, U.S.A.
Ono Pharmaceutical Co., Ltd., Osaka, Japan
Onuki General Foundation, Japan
Pharmaceutical Research Instrument Center, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
Pirkkanmaa Cancer Association, Tampere, Finland
Polish Ministry of Science and Higher Education, Warsaw, Poland
Promoted Research, Kanazawa Medical University, Uchinada, Japan
Rachadapisek Sompote Fund, Chulalongkorn University, Bangkok, Thailand
Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University, Bangkok, Thailand
Research Grant, Medical University of Lublin, Lublin, Poland
Research Grant, University of Malaya, Kuala Lumpur, Malaysia
Research Institute of Rangsit University, Rangsit University, Mueang Pathum Thani, Thailand
Rural Development Administration, Ministry of Trade, Industry, & Energy (MOTIE), Sejong, Republic of Korea
Samsung Medical Center Intramural Grant, Seoul, Republic of Korea
Sato Foundation, San Rafael, CA, U.S.A.
Scientific Research Projects Coordination Unit, Istanbul University, Istanbul, Turkey
Seoul National University, Seoul, Republic of Korea
Seppo Nieminen Legacy Fund, Finland
Signe and Ane Gyllenberg Foundation, Finland
Silpakorn University Research and Development Institute, Bangkok, Thailand
Statutory Funds, Department of Molecular and Cellular Biology, Wroclaw Medical University, Wroclaw, Poland
Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan
Support Project And R&D Company (SPARC), Korea Institute for Advancement of Technology (KIAT), Seoul, Republic of Korea
Taipei Veterans General Hospital, Taipei City, Taiwan R.O.C.
Taipei Veterans General Hospital, Yuan-Shan Branch, Yuan-Shan, Taiwan, R.O.C.
Taiwan Ministry of Health and Welfare (MOHW), Taipei, Taiwan, R.O.C.
Taiwan Ministry of Science and Technology (MOST), Taipei, Taiwan, R.O.C.
Takeda Science Foundation, Japan
Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan, R.O.C.
Thailand Research Fund, Bangkok, Thailand
Tissue Bank, China Medical University, Taichung, Taiwan, R.O.C.
Tri-Service General Hospital Foundation, Taipei, Taiwan, R.O.C.
University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province, P.R. China
University of Antofagasta, Antofagasta, Chile
University of California, Berkeley, CA, U.S.A.
University of Minas Gerais, Belo Horizonte, Brazil
University of Pernambuco, Pernambuco, Brazil
University of Turin, Turin, Italy
Victor Babes University of Medicine and Pharmacy Timisoara, Timisoara, Romania
Wilhelm-Sander Foundation, München, Germany
Wroclaw Medical University, Wroclaw, Poland
Wroclaw University of Technology, Wroclaw, Poland
Yakult Honsha Co., Ltd., Tokyo, Japan
Yeditepe University, Istanbul, Turkey
Yonsei University College of Medicine, Seoul, Republic of Korea
Instructions for Authors 2020

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis; 10. Retrospective studies and case reports. The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to peer-review, when appropriate, by two members of the Editorial Board. All manuscripts submitted to IN VIVO are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

Open Access Policy. IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 700.00 (effective January 1, 2020) for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 60.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume and issue numbers, as well as page numbering.

Copyright. Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in IN VIVO are the property of the publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Conflicts of Interest; (h) Authors’ contributions; (i) Acknowledgements; (j) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are not subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNNXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

Ethical Policies and Standards. IN VIVO agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html. In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfills the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to IV is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

4. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

5. Authors should pay attention to the following points when writing an article for IN VIVO:
   - The Instructions to Authors must be followed in every detail.
   - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   - Results given in figures should not be repeated in tables.
   - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by… authors, year).
   - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
   - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

8. Articles submitted to IN VIVO may be rejected without review if:
   - they do not fall within the journal’s policy.
   - they do not follow the instructions for authors.
   - language is unclear.
   - results are not sufficient to support a final conclusion.
   - results are not objectively based on valid experiments.
   - they repeat results already published by the same or other authors before the submission to IV.
   - plagiarism is detected by plagiarism screening services.
   - (Rejection rate (2016): 59%).

9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9:00-16:00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org.

11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

(Copyright© 2020 – International Institute of Anticancer Research (G.J. Delineasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.)